Starpharma Holdings Ltd. (OTCMKTS:SPHRY – Get Free Report) was the target of a significant growth in short interest in June. As of June 15th, there was short interest totaling 1 shares, a growth of ∞ from the May 31st total of 0 shares. Based on an average daily volume of 1,105 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the company are sold short.
Starpharma Price Performance
Starpharma stock opened at $4.75 on Thursday. Starpharma has a fifty-two week low of $0.55 and a fifty-two week high of $5.70. The stock has a 50-day simple moving average of $4.90 and a 200-day simple moving average of $3.66.
Starpharma Company Profile
Starpharma is a clinical-stage biopharmaceutical company specializing in the development of dendrimer-based products across infectious disease, oncology and ophthalmology. Its proprietary dendrimer platform, DEP™ (Dendrimer Enhanced Products), enables precise molecular engineering to enhance drug delivery, targeting and safety profiles. The company’s lead product, VivaGel®, is a topical microbicide that has been approved in multiple markets for the treatment and prevention of bacterial vaginosis and is in clinical development for antiviral applications.
In addition to VivaGel, Starpharma is advancing pipeline candidates that leverage DEP technology to improve the performance of established and novel therapeutic agents.
Recommended Stories
- Five stocks we like better than Starpharma
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Receive News & Ratings for Starpharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Starpharma and related companies with MarketBeat.com's FREE daily email newsletter.
